REFERENCES
1. Paray BA, Albeshr MF, Jan AT, Rather IA. Leaky gut and autoimmunity: an intricate balance in individuals health and the diseased state. Int J Mol Sci 2020;21:9770.
2. Laursen MF. Gut Microbiota Development: influence of diet from infancy to toddlerhood. Ann Nutr Metab 2021:1-14.
3. Reedy AR, Luo L, Neish AS, Jones RM. Commensal microbiota-induced redox signaling activates proliferative signals in the intestinal stem cell microenvironment. Development 2019;146:dev171520.
4. Campbell EL, Colgan SP. Control and dysregulation of redox signalling in the gastrointestinal tract. Nat Rev Gastroenterol Hepatol 2019;16:106-20.
5. Lucas K, Morris G, Anderson G, Maes M. The Toll-Like receptor radical cycle pathway: a new drug target in immune-related chronic fatigue. CNS Neurol Disord Drug Targets 2015;14:838-54.
6. Saint-Georges-Chaumet Y, Attaf D, Pelletier E, Edeas M. Targeting microbiota-mitochondria inter-talk: microbiota control mitochondria metabolism. Cell Mol Biol (Noisy-le-grand) 2015;61:121-4.
7. Liu S, Hu J, Shi C, et al. Sparstolonin B exerts beneficial effects on prostate cancer by acting on the reactive oxygen species-mediated PI3K/AKT pathway. J Cell Mol Med 2021;25:5511-24.
8. Zhao Y, Ma T, Zhang Z, et al. Resolvin D1 attenuates acid-induced DNA damage in esophageal epithelial cells and rat models of acid reflux. Eur J Pharmacol 2021;912:174571.
9. Zhang Z, Wang Y, Li Q. Mechanisms underlying the effects of stress on tumorigenesis and metastasis (Review). Int J Oncol 2018;53:2332-42.
10. Falone S, Santini S Jr, Cordone V, et al. Extremely low-frequency magnetic fields and redox-responsive pathways linked to cancer drug resistance: insights from co-exposure-based. in vitro ;6:33.
11. Szczyrek M, Mlak R, Krawczyk P, et al. Polymorphisms of genes encoding multidrug resistance proteins as a predictive factor for second-line docetaxel therapy in advanced non-small cell lung cancer. Pathol Oncol Res 2017;23:607-14.
12. Iranmanesh Y, Jiang B, Favour OC, et al. Mitochondria’s role in the maintenance of cancer stem cells in glioblastoma. Front Oncol 2021;11:582694.
13. Keenan J, Murphy L, Henry M, Meleady P, Clynes M. Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line. Proteomics 2009;9:1556-66.
14. Kang YB, Cai Y. Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer. World J Gastroenterol 2021;27:5362-75.
15. Grenda A, Krawczyk P. Cancer trigger or remedy: two faces of the human microbiome. Appl Microbiol Biotechnol 2021;105:1395-405.
16. Encarnação JC, Pires AS, Amaral RA, et al. Butyrate, a dietary fiber derivative that improves irinotecan effect in colon cancer cells. J Nutr Biochem 2018;56:183-92.
17. Santo C, Caseiro C, Martins MJ, Monteiro R, Brandão I. Gut microbiota, in the halfway between nutrition and lung function. Nutrients 2021;13:1716.
19. Sultan S, El-Mowafy M, Elgaml A, et al. Metabolic influences of gut microbiota dysbiosis on inflammatory bowel disease. Front Physiol 2021;12:715506.
20. Chen Y, Chen YX. Microbiota-associated metabolites and related immunoregulation in colorectal cancer. Cancers (Basel) 2021;13:4054.
21. Jalandra R, Dalal N, Yadav AK, et al. Emerging role of trimethylamine-N-oxide (TMAO) in colorectal cancer. Appl Microbiol Biotechnol 2021;105:7651-60.
22. Grover K, Gregory S, Gibbs JF, Emenaker NJ. A discussion of the gut microbiome’s development, determinants, and dysbiosis in cancers of the esophagus and stomach. J Gastrointest Oncol 2021;12:S290-300.
23. Temraz S, Nassar F, Kreidieh F, et al. Hepatocellular carcinoma immunotherapy and the potential influence of gut microbiome. Int J Mol Sci 2021;22:7800.
24. Brandi G, De Lorenzo S, Candela M, et al. Microbiota, NASH, HCC and the potential role of probiotics. Carcinogenesis 2017;38:231-40.
25. Golombos DM, Ayangbesan A, O’Malley P, et al. The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. Urology 2018;111:122-8.
26. Smith KS, Frugé AD, van der Pol W, et al. Gut microbial differences in breast and prostate cancer cases from two randomised controlled trials compared to matched cancer-free controls. Benef Microbes 2021;12:239-48.
27. Alpuim Costa D, Nobre JG, Batista MV, et al. Human microbiota and breast cancer-is there any relevant link? Front Microbiol 2021;12:584332.
28. Gadelle D, Raibaud P, Sacquet E. Beta-Glucuronidase activities of intestinal bacteria determined both. in vitro ;49:682-5.
29. Liu X, Cheng Y, Zang D, et al. The role of gut microbiota in lung cancer: from carcinogenesis to immunotherapy. Front Oncol 2021;11:720842.
30. Shi Z, Zhang M. Emerging roles for the gut microbiome in lymphoid neoplasms. Clin Med Insights Oncol 2021;15:11795549211024197.
31. Mitsuhashi K, Nosho K, Sukawa Y, et al. Association of fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget 2015;6:7209-20.
32. Baysal B, İnce AT, Gültepe B, et al. Helicobacter pylori is undetectable in intraductal papillary mucinous neoplasm. Pancreatology 2016;16:865-8.
33. Rabelo-Gonçalves EM, Roesler BM, Zeitune JM. Extragastric manifestations of Helicobacter pylori infection: Possible role of bacterium in liver and pancreas diseases. World J Hepatol 2015;7:2968-79.
34. Ketpueak T, Thiennimitr P, Apaijai N, Chattipakorn SC, Chattipakorn N. Association of chronic opisthorchis infestation and microbiota alteration on tumorigenesis in cholangiocarcinoma. Clin Transl Gastroenterol 2020;12:e00292.
35. Jauvain M, Courtois S, Lehours P, Bessède E. Metformin modifies the gut microbiota of mice infected with. helicobacter pylori ;14:329.
36. Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science 2018;359:1366-70.
37. Veziant J, Villéger R, Barnich N, Bonnet M. Gut microbiota as potential biomarker and/or therapeutic target to improve the management of cancer: focus on colibactin-producing. escherichia coli ;13:2215.
38. van Praagh JB, de Goffau MC, Bakker IS, et al. Mucus microbiome of anastomotic tissue during surgery has predictive value for colorectal anastomotic leakage. Ann Surg 2019;269:911-6.
39. Zidi O, Souai N, Raies H, et al. Fecal metabolic profiling of breast cancer patients during neoadjuvant chemotherapy reveals potential biomarkers. Molecules 2021;26:2266.
40. Parker KD, Maurya AK, Ibrahim H, et al. Dietary rice bran-modified human gut microbial consortia confers protection against colon carcinogenesis following fecal transfaunation. Biomedicines 2021;9:144.
41. Kaźmierczak-Siedlecka K, Daca A, Fic M, et al. Therapeutic methods of gut microbiota modification in colorectal cancer management - fecal microbiota transplantation, prebiotics, probiotics, and synbiotics. Gut Microbes 2020;11:1518-30.
42. Mehmood K, Moin A, Hussain T, et al. Can manipulation of gut microbiota really be transformed into an intervention strategy for cardiovascular disease management? Folia Microbiol (Praha) 2021;66:897-916.
43. Waziri A, Bharti C, Aslam M, et al. Probiotics for the chemoprotective role against the toxic effect of cancer chemotherapy. Anticancer Agents Med Chem 2022;22:654-67.
44. Liu ZH, Huang MJ, Zhang XW, et al. The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: a double-center and double-blind randomized clinical trial. Am J Clin Nutr 2013;97:117-26.
45. Wang Y, Ma R, Liu F, Lee SA, Zhang L. Modulation of gut microbiota: a novel paradigm of enhancing the efficacy of programmed death-1 and programmed death ligand-1 blockade therapy. Front Immunol 2018;9:374.
46. Mo Q, Liu T, Fu A, et al. Novel gut microbiota patterns involved in the attenuation of dextran sodium sulfate-induced mouse colitis mediated by glycerol monolaurate via inducing anti-inflammatory responses. mBio 2021;12:e0214821.
47. Blanco-Pérez F, Steigerwald H, Schülke S, et al. The dietary fiber pectin: health benefits and potential for the treatment of allergies by modulation of gut microbiota. Curr Allergy Asthma Rep 2021;21:43.
49. Panebianco C, Andriulli A, Pazienza V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome 2018;6:92.
50. Alexander JL, Wilson ID, Teare J, et al. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol 2017;14:356-65.
51. Gagnière J, Raisch J, Veziant J, et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol 2016;22:501-18.
52. Pellon A, Barriales D, Peña-Cearra A, et al. The commensal bacterium. Lactiplantibacillus plantarum ;13:1939598.
53. Zhu W, Liu Y, Zhang W, et al. Selenomethionine protects hematopoietic stem/progenitor cells against cobalt nanoparticles by stimulating antioxidant actions and DNA repair functions. Aging (Albany NY) 2021;13:11705-26.
54. Genua F, Raghunathan V, Jenab M, Gallagher WM, Hughes DJ. The role of gut barrier dysfunction and microbiome dysbiosis in colorectal cancer development. Front Oncol 2021;11:626349.
55. Halcrow PW, Lynch ML, Geiger JD, Ohm JE. Role of endolysosome function in iron metabolism and brain carcinogenesis. Semin Cancer Biol 2021;76:74-85.
56. Guo H, Liu H, Wu H, et al. Nickel carcinogenesis mechanism: DNA damage. Int J Mol Sci 2019;20:4690.
57. Zhou X, Li J, Sun JL. Oral nickel changes of intestinal microflora in mice. Curr Microbiol 2019;76:590-6.
58. Borsani B, De Santis R, Perico V, et al. The role of carrageenan in inflammatory bowel diseases and allergic reactions: where do we stand? Nutrients 2021;13:3402.
59. Selivanov VA, Zagubnaya OA, Nartsissov YR, Cascante M. Unveiling a key role of oxaloacetate-glutamate interaction in regulation of respiration and ROS generation in nonsynaptic brain mitochondria using a kinetic model. PLoS One 2021;16:e0255164.
60. Canton M, Sánchez-Rodríguez R, Spera I, et al. Reactive oxygen species in macrophages: sources and targets. Front Immunol 2021;12:734229.
61. Meijles DN, Zoumpoulidou G, Markou T, et al. The cardiomyocyte “redox rheostat”: Redox signalling via the AMPK-mTOR axis and regulation of gene and protein expression balancing survival and death. J Mol Cell Cardiol 2019;129:118-29.
62. Davoodi P, Srinivasan MP, Wang CH. Effective co-delivery of nutlin-3a and p53 genes via core-shell microparticles for disruption of MDM2-p53 interaction and reactivation of p53 in hepatocellular carcinoma. J Mater Chem B 2017;5:5816-34.
63. Choi JA, Cho SN, Lee J, et al. Lipocalin 2 regulates expression of MHC class I molecules in mycobacterium tuberculosis-infected dendritic cells via ROS production. Cell Biosci 2021;11:175.
64. Moreira TG, Mangani D, Cox LM, et al. PD-L1+ and XCR1+ dendritic cells are region-specific regulators of gut homeostasis. Nat Commun 2021;12:4907.
65. Chougnet CA, Thacker RI, Shehata HM, et al. Loss of phagocytic and antigen cross-presenting capacity in aging dendritic cells is associated with mitochondrial dysfunction. J Immunol 2015;195:2624-32.
66. Din AU, Hassan A, Zhu Y, et al. Inhibitory effect of bifidobacterium bifidum ATCC 29521 on colitis and its mechanism. J Nutr Biochem 2020;79:108353.
67. Lee JY, Bae E, Kim HY, et al. High-fat-diet-induced oxidative stress linked to the increased colonization of lactobacillus. sakei ;9:e0007421.
68. Garcia-Gonzalez N, Prete R, Perugini M, et al. Probiotic antigenotoxic activity as a DNA bioprotective tool: a minireview with focus on endocrine disruptors. FEMS Microbiol Lett 2020;367:fnaa041.
69. Davoodvandi A, Marzban H, Goleij P, et al. Effects of therapeutic probiotics on modulation of microRNAs. Cell Commun Signal 2021;19:4.
70. Heydari Z, Rahaie M, Alizadeh AM, et al. Effects of lactobacillus acidophilus and bifidobacterium bifidum probiotics on the expression of microRNAs 135b, 26b, 18a and 155, and their involving genes in mice colon cancer. Probiotics Antimicrob Proteins 2019;11:1155-62.
71. Li Y, Choi PS, Casey SC, Dill DL, Felsher DW. MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell 2014;26:262-72.
72. Shires J, Theodoridis E, Hayday AC. Biological insights into TCRγδ+ and TCRαβ+ intraepithelial lymphocytes provided by serial analysis of gene expression (SAGE). Immunity 2001;15:419-34.
73. Zhu R, Li W, Xu Y, Wan J, Zhang Z. Upregulation of BTG1 enhances the radiation sensitivity of human breast cancer in vitro and in vivo. Oncol Rep 2015;34:3017-24.
75. Imran M, Lim IK. Regulation of Btg2(/TIS21/PC3) expression via reactive oxygen species-protein kinase C-ΝFκΒ pathway under stress conditions. Cell Signal 2013;25:2400-12.
76. Sundaramoorthy S, Ryu MS, Lim IK. B-cell translocation gene 2 mediates crosstalk between PI3K/Akt1 and NFκB pathways which enhances transcription of MnSOD by accelerating IκBα degradation in normal and cancer cells. Cell Commun Signal 2013;11:69.
77. Suzuki T, Tsuzuku J, Hayashi A, et al. Inhibition of DNA damage-induced apoptosis through Cdc7-mediated stabilization of Tob. J Biol Chem 2012;287:40256-65.
78. Guan R, Peng L, Wang D, et al. Decreased TOB1 expression and increased phosphorylation of nuclear TOB1 promotes gastric cancer. Oncotarget 2017;8:75243-53.
79. Matsuda S, Rouault J, Magaud J, Berthet C. In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS Letters 2001;497:67-72.
80. Doidge R, Mittal S, Aslam A, Winkler GS. The anti-proliferative activity of BTG/TOB proteins is mediated via the Caf1a (CNOT7) and Caf1b (CNOT8) deadenylase subunits of the Ccr4-not complex. PLoS One 2012;7:e51331.
81. Yang X, Morita M, Wang H, et al. Crystal structures of human BTG2 and mouse TIS21 involved in suppression of CAF1 deadenylase activity. Nucleic Acids Res 2008;36:6872-81.
82. Amine H, Ripin N, Sharma S, et al. A conserved motif in human BTG1 and BTG2 proteins mediates interaction with the poly(A) binding protein PABPC1 to stimulate mRNA deadenylation. RNA Biol 2021;18:2450-65.
83. Chapat C, Chettab K, Simonet P, et al. Alternative splicing of CNOT7 diversifies CCR4-NOT functions. Nucleic Acids Res 2017;45:8508-23.
84. Horiuchi M, Takeuchi K, Noda N, et al. Structural basis for the antiproliferative activity of the Tob-hCaf1 complex. J Biol Chem 2009;284:13244-55.
85. Lim NS, Kozlov G, Chang TC, et al. Comparative peptide binding studies of the PABC domains from the ubiquitin-protein isopeptide ligase HYD and poly(A)-binding protein. Implications for HYD function. J Biol Chem 2006;281:14376-82.
86. Ezzeddine N, Chen CY, Shyu AB. Evidence providing new insights into TOB-promoted deadenylation and supporting a link between TOB’s deadenylation-enhancing and antiproliferative activities. Mol Cell Biol 2012;32:1089-98.
87. Stupfler B, Birck C, Séraphin B, Mauxion F. BTG2 bridges PABPC1 RNA-binding domains and CAF1 deadenylase to control cell proliferation. Nat Commun 2016;7:10811.
88. Hwang SS, Lim J, Yu Z, et al. mRNA destabilization by BTG1 and BTG2 maintains T cell quiescence. Science 2020;367:1255-60.
89. Räsch F, Weber R, Izaurralde E, Igreja C. 4E-T-bound mRNAs are stored in a silenced and deadenylated form. Genes Dev 2020;34:847-60.
90. Fabian MR, Mathonnet G, Sundermeier T, et al. Mammalian miRNA RISC recruits CAF1 and PABP to affect PABP-dependent deadenylation. Mol Cell 2009;35:868-80.
91. Flamand MN, Wu E, Vashisht A, et al. Poly(A)-binding proteins are required for microRNA-mediated silencing and to promote target deadenylation in C. elegans. Nucleic Acids Res 2016;44:5924-35.
92. Collart MA, Panasenko OO. The Ccr4-Not Complex: Architecture and Structural Insights. Subcell Biochem 2017;83:349-79.
93. Mao B, Zhang Z, Wang G. BTG2: a rising star of tumor suppressors (review). Int J Oncol 2015;46:459-64.
94. Peng C, Ouyang Y, Lu N, Li N. The NF-κB Signaling Pathway, the Microbiota, and Gastrointestinal Tumorigenesis: Recent Advances. Front Immunol 2020;11:1387.
95. Gu S, Zaidi S, Hassan MI, et al. Mutated ceacams disrupt transforming growth factor beta signaling and alter the intestinal microbiome to promote colorectal carcinogenesis. Gastroenterology 2020;158:238-52.
96. Lang M, Baumgartner M, Rożalska A, et al. Crypt residing bacteria and proximal colonic carcinogenesis in a mouse model of lynch syndrome. Int J Cancer 2020;147:2316-26.
97. Ke A, Parreira VR, Goodridge L, Farber JM. Current and future perspectives on the role of probiotics, prebiotics, and synbiotics in controlling pathogenic. cronobacter ;12:755083.
98. Genton L, Lazarevic V, Stojanovic O, et al. Metataxonomic and metabolic impact of fecal microbiota transplantation from patients with pancreatic cancer into germ-free mice: a pilot study. Front Cell Infect Microbiol 2021;11:752889.
99. Sambrani R, Abdolalizadeh J, Kohan L, Jafari B. Recent advances in the application of probiotic yeasts, particularly saccharomyces, as an adjuvant therapy in the management of cancer with focus on colorectal cancer. Mol Biol Rep 2021;48:951-60.
100. Lima WG, Pessoa RM, Vital KD, et al. Effect of probiotics on the maintenance of intestinal homeostasis after chemotherapy: systematic review and meta-analysis of pre-clinical studies. Benef Microbes 2020;11:305-18.
